

23. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP 2006 Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. *Thorax* 61:895–902
24. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, Omura S, Yamamoto K, Ito K 2000 Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. *Biochem Biophys Res Commun* 267:124–128
25. Takizawa H, Desaki M, Ohtoshi T, Kikutani T, Okazaki H, Sato M, Akiyama N, Shoji S, Hiramato K, Ito K 1995 Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. *Biochem Biophys Res Commun* 210:781–786
26. Ivetic Tkalecic V, Bosnjak B, Hrvacic B, Bosnar M, Marjanovic N, Ferencic Z, Situm K, Culic O, Parnham MJ, Erakovic V 2006 Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. *Eur J Pharmacol* 539:131–138
27. Di Paolo A, Barbara C, Chella A, Angeletti CA, Del Tacca M 2002 Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. *Pharmacol Res* 46:545–550
28. Nightingale CH 1997 Pharmacokinetics and pharmacodynamics of newer macrolides. *Pediatr Infect Dis J* 16:438–443
29. Blau H, Klein K, Shalit I, Halperin D, Fabian I 2007 Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. *Am J Physiol Lung Cell Mol Physiol* 292:L343–L352
30. Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, Takizawa H 2004 Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. *Antimicrob Agents Chemother* 48:1581–1585
31. Cigana C, Nicolis E, Passeto M, Assael BM, Mellotti P 2006 Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. *Biochem Biophys Res Commun* 350:977–982
32. Li YH, Yan ZQ, Jensen JS, Tullus K, Brauner A 2000 Activation of nuclear factor kappaB and induction of inducible nitric oxide synthase by *Ureaplasma urealyticum* in macrophages. *Infect Immun* 68:7087–7093
33. Schelonka RL, Waites KB 2007 *Ureaplasma* infection and neonatal lung disease. *Semin Perinatol* 31:2–9

## Erratum

In the article, “Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats” by Frans J.C. Cuperus *et al.* (*Pediatr Res* 59:506–512), the authors report that the fractional turnover of <sup>3</sup>H-unconjugated bilirubin was erroneously calculated from *log*10 instead of *ln* (natural logarithmic) semi-logarithmic plots of the specific activity. The reported fractional turnover (Table 2, Fig. 3 and Fig. 4) and total turnover (Table 2) should therefore be multiplied with 2.3 in all experimental groups. As a result, the *net* transmucosal flux of unconjugated bilirubin (UCB; Fig. 4), calculated as the difference between fractional turnover and fractional biliary excretion, increases in all experimental groups. Corrected information is presented in Table 1 of this erratum.

The corrected information does not affect the main findings of the study. Significance levels and the linear relation (Table 2 and Fig. 3) are unaltered, and the interpretation of data in these figures remains unchanged. The corrected *net* transmucosal flux (Fig. 4) indicates transmucosal UCB excretion into the intestinal lumen in all experimental groups, rather than only in the orlistat- and the combined orlistat and phototherapy group. This implies that, as indicated by Schmid and Hammaker (*J Clin Invest* 42:1720), under control conditions, transmucosal UCB excretion is an important secretory pathway in Gunn rats. The study shows that this secretory pathway is enhanced by orlistat treatment.

**Table 1.** Corrected fractional turnover and total turnover of <sup>3</sup>H-bilirubin and net transmucosal UCB flux

	Controls (n = 6)	Orlistat (n = 5)	PT (n = 4)	Orlistat + PT (n = 4)
Fractional turnover <sup>3</sup> H-UCB (%/h)	1.36 ± 0.53	2.30 ± 0.15*	2.97 ± 0.29§	
Total turnover bilirubin (nmol/h per 100 g BW)	2.10 ± 0.47†	84.3 ± 11.1	84.3 ± 7.6	
<i>Net</i> transmucosal UCB flux (% of exchangeable bilirubin pool excreted/h)	0.74**	1.42**	1.27**	2.28**

Data represent mean ± SD. For calculation of fluxes see Methods section.

\* *p* < 0.05, † *p* = 0.058, § *p* < 0.001 compared with controls.

† *p* < 0.05 compared with orlistat + PT.

\*\* The estimated *net* transmucosal flux is directed from the blood into the intestinal lumen in all experimental groups. This is the corrected flux [E] from Figure 4 in the original paper.